ReviewVaccine2019
New human rabies vaccines in the pipeline.
Review in Vaccine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 39 citations in OpenAlex.
- A Rabies Virus Nucleocapsid-like Nanostructure Vaccine Based on Dual-Cationic Lipid Nanoparticles.Vaccines · 2025Article
- A novel single-vector featuring bidirectional promoters for production of bispecific antibody against rabies virus.BMC biotechnology · 2025Article
- Deep mutational scanning of rabies glycoprotein defines mutational constraint and antibody-escape mutations.Cell host & microbe · 2025Article
- Five Amino Acid Substitutions in the S1 Unit of Infectious Bronchitis Virus Are Critical Determinants Enhancing Its Adaptation to Vero Cells.Veterinary sciences · 2025Article
- Duplication of the Rabies Virus Glycoprotein Enhances the Virus Propagation Rate and Immunogenicity.Advanced biomedical research · 2025Article
- A single dose of an ALVAC vector-based RABV virus-like particle candidate vaccine induces a potent immune response in mice, cats and dogs.Emerging microbes & infections · 2024Article
- Safety and efficacy assessment of an mRNA rabies vaccine in dogs, rodents, and cynomolgus macaques.NPJ vaccines · 2024Article
- A single immunization with core-shell structured lipopolyplex mRNA vaccine against rabies induces potent humoral immunity in mice and dogs.Emerging microbes & infections · 2023Article
- Sf9 Cells Metabolism and Viability When Coinfected with Two Monocistronic Baculoviruses to Produce Rabies Virus-like Particles.Molecular biotechnology · 2023Article
- Developments in Rabies Vaccines: The Path Traversed from Pasteur to the Modern Era of Immunization.Vaccines · 2023Review
- Biosafety Practices When Working with Bats: A Guide to Field Research Considerations.Applied biosafety : journal of the American Biological Safety Association · 2022Article
- Microneedle-Based Vaccine Delivery: Review of an Emerging Technology.AAPS PharmSciTech · 2022Review
- Formulation and Delivery Technologies for mRNA Vaccines.Current topics in microbiology and immunology · 2022Article
- A next generation vaccine against human rabies based on a single dose of a chimpanzee adenovirus vector serotype C.PLoS neglected tropical diseases · 2020Article
- Advances in RNA Vaccines for Preventive Indications: A Case Study of A Vaccine Against Rabies.Vaccines · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rabies remains endemic in more than 150 countries. In 99% of human cases, rabies virus is transmitted by dogs. The disease, which is nearly always fatal, is preventable by vaccines given either before and/or after exposure to a rabid animal. Numerous factors including the high cost of vaccines, the relative complexity of post-exposure vaccination protocols requiring multiple doses of vaccine, which in cases of severe exposure have to be combined with a rabies immune globulin, lack of access to health care, and insufficient surveillance contribute to the estimated 59,000 human deaths caused by rabies each year. New, less expensive and more immunogenic rabies vaccines are needed together with improved surveillance and dog rabies control to reduce the death toll of human rabies. Here, we discuss new rabies vaccines that are in clinical and pre-clinical testing and evaluate their potential to replace current vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.